| Market Cap | 64.85M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -17.69M | Forward P/E | -12.89 | EPS next Y | - | 50D Avg Chg | -11.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -10.00% |
| Dividend | N/A | Price/Book | 3.31 | EPS next 5Y | - | 52W High Chg | -54.00% |
| Recommedations | 2.00 | Quick Ratio | 1.09 | Shares Outstanding | 101.51M | 52W Low Chg | 29.00% |
| Insider Own | 38.17% | ROA | -58.15% | Shares Float | 62.17M | Beta | 0.19 |
| Inst Own | 0.90% | ROE | -140.93% | Shares Shorted/Prior | 41.91K/274.70K | Price | 0.64 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 125,445 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 21,381 | Change | 2.33% |
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.